Characterization of APOE Christchurch carriers in 455,306 UK Biobank participants
Open Access
- 28 November 2023
- journal article
- letter
- Published by Springer Nature in Molecular Neurodegeneration
- Vol. 18 (1) , 1-4
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- Apolipoprotein B is a novel marker for early tau pathology in Alzheimer's diseaseAlzheimer's & Dementia, 2021
- Genetics of 35 blood and urine biomarkers in the UK BiobankNature Genetics, 2021
- Heterozygous APOE Christchurch in familial Alzheimer’s disease without mutations in other Mendelian genesNeuropathology and Applied Neurobiology, 2020
- APOE and dementia – resequencing and genotyping in 105,597 individualsAlzheimer's & Dementia, 2020
- Resistance to autosomal dominant Alzheimer’s disease in an APOE3 Christchurch homozygote: a case reportNature Medicine, 2019
- Apolipoprotein E and Alzheimer disease: pathobiology and targeting strategiesNature Reviews Neurology, 2019
- Association of Early-Onset Alzheimer Disease With Elevated Low-Density Lipoprotein Cholesterol Levels and Rare Genetic Coding Variants of APOBJAMA Neurology, 2019
- Genome-wide association study of medication-use and associated disease in the UK BiobankNature Communications, 2019
- Plasma Apolipoprotein Levels Are Associated with Cognitive Status and Decline in a Community Cohort of Older IndividualsPLOS ONE, 2012
- Apolipoprotein E: Cholesterol Transport Protein with Expanding Role in Cell BiologyScience, 1988